Nat Genet:表观遗传变化让远端转移的胰腺癌细胞更具生存优势

2017-01-18 佚名 生物谷

一项多中心研究报告称,对死于胰腺癌的病人肿瘤样本进行的全基因组分析表明DNA上发生的表观遗传修饰能够使一些胰腺癌细胞获得生存优势,据研究人员介绍,这些优势能够让癌细胞在肝脏和肺这样血液供应充足的器官繁荣生长。相关研究结果发表在国际学术期刊Nature Genetics上。癌症转移会让癌症变得非常致命,手术和其他治疗方法无法发现并摧毁每一个癌细胞,对于胰腺癌来说尤为如此,在发生转移之前一般很


一项多中心研究报告称,对死于胰腺癌的病人肿瘤样本进行的全基因组分析表明DNA上发生的表观遗传修饰能够使一些胰腺癌细胞获得生存优势,据研究人员介绍,这些优势能够让癌细胞在肝脏和肺这样血液供应充足的器官繁荣生长。相关研究结果发表在国际学术期刊Nature Genetics上。

癌症转移会让癌症变得非常致命,手术和其他治疗方法无法发现并摧毁每一个癌细胞,对于胰腺癌来说尤为如此,在发生转移之前一般很难检测到肿瘤的存在。

为了更好地理解胰腺癌转移灶的形成,纪念斯隆卡特琳癌症中心的研究人员从8位死于胰腺导管腺癌的病人身上收集了肿瘤组织样本,样本取自原位肿瘤和任何可以检测到的转移肿瘤。研究人员对肿瘤的基因组进行了分析,寻找基因突变和DNA上发生的变化,在另外一篇发表的文章中他们报告称并未发现与癌细胞成功转移有直接关联的基因突变。

随后研究人员又对肿瘤细胞的表观遗传学变化进行了分析,他们表示发生局部扩散的肿瘤中并没有出现显著变化,但是转移到肺和肝脏的远端转移灶以及原位肿瘤中都存在大量表观遗传学变化。研究人员认为其中一个解释可能是:“远端转移灶的形成需要癌细胞沿着血管跨越很长距离最后在一个适宜环境中着陆并开始形成肿瘤,而发生局部转移的癌细胞仅仅突破了原位肿瘤,仍然生存在一个类似的环境中,因此与原位肿瘤更加相似。”

表观遗传变化能够影响基因活性,研究人员根据功能对受到影响的基因进行了归类,观察基因表达的改变是否会对同一个病人体内不同的亚克隆造成特定的结果。分析结果表明许多受到影响的基因都会赋予癌细胞生存优势,比如增强细胞迁移能力或抵抗化疗药物的能力。

为了探索表观遗传变化的原因,研究人员进行了生化分析发现远端转移的肿瘤会比局部转移的肿瘤消耗更多的葡萄糖,远端转移的肿瘤细胞及其祖细胞能够通过戊糖磷酸途径对葡萄糖进行代谢从而促进生长,6-磷酸葡萄糖酸脱氢酶(PGD)是该途径中一个重要的酶。

研究人员用PGD的一种抑制剂药物6AN处理同一个病人不同转移灶的肿瘤细胞,发现这种药物不会引起局部转移肿瘤细胞的DNA发生表观遗传变化,但是能够逆转远端转移灶肿瘤细胞的表观遗传变化。6AN还可以下调与癌症扩散有关的基因活性,并强力阻止远端转移灶的形成。

研究人员表示还需要进一步理解癌症转移过程中发生的复杂遗传学和生物学变化,他们也在努力研究戊糖磷酸途径的激活如何导致了大量的表观遗传学变化,他们希望这些研究能够帮助开发新药物用于侵袭性癌症的治疗。

原始出处

Oliver G McDonald, Xin Li, Tyler Saunders, Rakel Tryggvadottir.et.al.Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.Nat Genet.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
    2017-07-31 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
    2017-08-13 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
    2017-01-22 liye789132251
  7. [GetPortalCommentsPageByObjectIdResponse(id=1747687, encodeId=8b511e4768705, content=<a href='/topic/show?id=226694485c6' target=_blank style='color:#2F92EE;'>#远端转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94485, encryptionId=226694485c6, topicName=远端转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dd635942810, createdName=lixiaol, createdTime=Mon Apr 10 20:55:00 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048759, encodeId=167a2048e5903, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Jul 31 22:55:00 CST 2017, time=2017-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733814, encodeId=298a1e3381474, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Aug 13 10:55:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686049, encodeId=46b3168604920, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Oct 31 17:55:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076837, encodeId=d76120e6837eb, content=<a href='/topic/show?id=17a36898514' target=_blank style='color:#2F92EE;'>#生存优势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68985, encryptionId=17a36898514, topicName=生存优势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 01 11:55:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881627, encodeId=9e19188162eba, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Jan 22 08:55:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252181, encodeId=993412521815f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jan 20 07:55:00 CST 2017, time=2017-01-20, status=1, ipAttribution=)]
    2017-01-20 yxch36

相关资讯

Epizyme表观遗传药物IND申请被FDA受理

今天美国生物技术公司Epizyme的表观遗传药物、EZH2抑制剂tazemetostat的IND申请被FDA受理,将开始BAP1缺失间皮瘤的临床开发。40-60%的新发生间皮瘤属于BAP1缺失型,Epizyme准备今年第三季度开始间皮瘤的二期临床试验。Tazemetostat已经在淋巴瘤的二期临床研究中。 每年IND有很多,但是因为表观遗传药物虽然可能有很大潜力但目前还处于艰难的爬坡阶段,所

Cell子刊:癌症研究的八大问题

最近,Cell出版社推出旗下新子刊Trends in Cancer,作为创刊号的一部分,该杂志邀请世界领先的癌症研究学者,列出了目前癌症研究领域所面临的八大问题。1、对于致癌突变的了解,如何才能指导治疗?科学家们花了几十年时间,来了解可导致细胞分裂失控的精确基因突变。现在癌症患者可以通过自己肿瘤的基因测序,来确定他们疾病的遗传根源,我们已经靶定了其中许多遗传学改变,但我们仍然还没有获得绝大部分

盘点:肿瘤干细胞——星星之火 可以燎原

肿瘤干细胞 表观遗传 乳腺癌 大肠癌 p53 西兰花 双重装备促使纳米颗粒精准狙杀癌症干细 中国科学家发现肝癌干细胞自我更新调控新机制胞 姜黄素抑制肝癌干细胞生长 肝癌治疗新提示 趋化因子受体CCR7促进乳腺癌肿瘤干细胞生长

首次发现父亲心理应激影响子代糖代谢

上海交大医学院研究员陈学进课题组和瑞金医院教授李小英课题组合作,首次发现父亲的心理应激通过表观遗传等机制可调控子代的糖代谢状况,进一步证实了环境因素介导的跨代遗传调控作用。相关研究成果近日发表于《细胞代谢》。 大量人群流行病学研究表明,心理应激与多个疾病的发生发展密切相关。近来的研究表明,母亲的心理应激,尤其是妊娠期间的应激,可促进子代肥胖和Ⅱ型糖尿病的发生。但父亲应激能否影响或调控子代的糖

Oncogene:靶向表观遗传修饰 抗击晚期癌症

近日,由Mayo Clinic肿瘤学家领导的国际研究小组发现了一种鉴定并有可能阻止许多晚期癌症继续进展的新方法,相关研究成果发表在国际学术期刊Oncogene上。   这篇文章主要对肾脏癌症及其转移进行了重点研究。但在之前一些对不同癌症类型中相同表观遗传印记的研究已经表明利用这种共同的信号途径或许可以帮助提高对晚期癌症的诊断率和治疗效果。   研究人员这样说道:“如果把

Nature子刊发表表观遗传学新成果 揭示与生育有关的重要机制

高等生物的基因组DNA围绕着由四种组蛋白组成的八聚体,形成碟状的核小体结构。基因组DNA以这样的形式包装成为染色质,使DNA受到良好的保护。通过“读取”模块识别组蛋白修饰是表观遗传学调控的一个主要机制。十一月十四日Nature Communications杂志发表的一项新研究揭示了小鼠生殖细胞生成中的一个重要机制。Johns Hopkins大学医学院、Rice大学和Wisconsin-Madiso